Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2017

View Archived Issues

Pan-CK2 inhibitor BMS-159 chosen for development as anticancer candidate

IdeS reduces donor-specific antibodies allowing for HLA-incompatible transplantation

Genentech presents data from phase I trial of influenza B candidate MHAB-5553A

BMP inhibition a novel pharmacological strategy for multiple hereditary exostoses

Trisubstituted benzene CGRP antagonists for migraine created at Merck & Co.

PharmAkea completes phase I study of PAT-1251

New phase IIa trial tests S. hominis lotion for atopic dermatitis

Sun Pharma Advanced Research discovers novel Bruton tyrosine kinase inhibitors

Pharmakea presents new lysyl oxidase homolog 2 inhibitors

Takeda submits Japanese NDA for vedolizumab for ulcerative colitis

FDA grants orphan drug designation to Jotrol for Friedreich's ataxia

CIRM grant supports Cellerant's development of CLT030-ADC for AML

Phase Ib results reported for proinsulin peptide immunotherapy in subjects with type 1 diabetes

AC Immune expands neurodegenerative pipeline with new antibodies against alpha-synuclein and TDP-43

Topas signs research and option agreement with Lilly focused on antigen-specific tolerance induction

Janssen describes synthesis of GPR40 full agonists for type 2 diabetes

CRISPR Therapeutics and Massachusetts General Hospital collaborate to develop T-cell therapies

Obesity compounds begin phase I trials under Zealand and Boehringer Ingelheim collaboration

Phase III study of Ace-ER in GNE myopathy misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...